ERBB2 and breast carcinoma: Interestingly, the 2014 ASCO treatment guidelines in HER2- breast cancer stated that creating evidence-based recommendations on treatments is challenging in patients with comorbidities, especially as evidence for drug efficacy is often from clinical trials, which generally exclude patients with comorbidities.